4D Molecular Therapeutics (NASDAQ:FDMT) Releases Earnings Results, Misses Expectations By $0.04 EPS

by · The Cerbat Gem

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04), Zacks reports. The business had revenue of $3.05 million for the quarter, compared to analyst estimates of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 37.26% and a negative net margin of 182.34%.

4D Molecular Therapeutics Stock Up 2.1%

NASDAQ FDMT traded up $0.21 during trading on Friday, hitting $10.14. The stock had a trading volume of 832,043 shares, compared to its average volume of 698,501. The company has a market capitalization of $530.12 million, a PE ratio of -3.95 and a beta of 2.77. The firm has a 50 day moving average price of $9.38 and a 200 day moving average price of $9.49. 4D Molecular Therapeutics has a twelve month low of $3.00 and a twelve month high of $12.34.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on FDMT. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Monday, April 20th. Wall Street Zen downgraded 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Barclays began coverage on 4D Molecular Therapeutics in a research report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 price objective for the company. The Goldman Sachs Group set a $33.00 price objective on 4D Molecular Therapeutics in a research report on Friday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.88.

Check Out Our Latest Stock Report on 4D Molecular Therapeutics

Hedge Funds Weigh In On 4D Molecular Therapeutics

Institutional investors have recently bought and sold shares of the company. Wexford Capital LP acquired a new position in 4D Molecular Therapeutics in the 3rd quarter valued at about $41,000. Daiwa Securities Group Inc. grew its position in shares of 4D Molecular Therapeutics by 3,362.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after buying an additional 6,186 shares in the last quarter. Susquehanna Portfolio Strategies LLC acquired a new position in shares of 4D Molecular Therapeutics during the fourth quarter worth about $77,000. Martingale Asset Management L P grew its position in shares of 4D Molecular Therapeutics by 12.4% during the fourth quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock worth $88,000 after buying an additional 1,303 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of 4D Molecular Therapeutics during the first quarter worth about $39,000. 99.27% of the stock is owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

(Get Free Report)

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.

See Also